Gynecological

 
  • GOG-0281 A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in patients with recurrent or progressive low-grade serous Ovarian cancer or Peritoneal Cancer

  • GY-004 A Phase III study comparing single-agent olaparib or the combination of cediranib and olaparib to standard platinum-based chemotherapy in women with recurrent platinum-sensitive ovarian, fallopian tube, or primary peritoneal cancer

For more information, contact Cheryl Patz, RN, OCN, CCRC, at 360-788-8238 or Mia Johnson, RN, at 360-788-8240